When to consider dose reduction during long-term use of eltrombopag/eltrombopag

Long-term management of chronic immune thrombocytopenia (ITP) often requires continued treatment with TPO receptor agonists. Although some patients may experience remission, most require maintenance treatment. Among the many options, Eltrombopag/Eltrombopag has become the first choice for many patients due to its unique efficacy and half-life characteristics. The plasma elimination half-life of eltrombopag in healthy people is 21-32 hours, while the half-life in ITP type 1 patients is extended to 26-35 hours. This means that its effects last for a relatively long time, so dosing it less frequently than once a day is entirely feasible.

When a patient's platelet count reaches or exceeds200×109L, a dose reduction of eltrombopag usually needs to be considered. Unlike traditional daily dose reduction methods, it is recommended that patients be switched to the same daily dose of eltrombopag 5 days per week rather than directly reducing the daily dose. This strategy allows patients to reduce the frequency of drug intake while maintaining treatment effects.

Over the next 2 weeks, the platelet count will be re-evaluated based on the patient's specific situation or the recommendation of the physician. If the platelet count remains stable, further reduction in dosing frequency may be considered until the platelet count stabilizes in the range of 20-100×109L or higher. This flexible dosing regimen not only provides patients with greater convenience, but also helps them better manage their disease in their daily lives.

The starting dose of eltrombopag is usually 50 mg daily (for patients of East Asian descent, the starting dose is 25 mg). Physicians will adjust the daily dose based on the patient's platelet response to achieve a target platelet count of 50-200×109L. In contrast, another strategy recommends starting with 50-75 mg per day (25 mg per day for East Asian patients) and then gradually reducing the dose weekly to achieve a platelet count of ≥20 × 109L. Although this target is relatively low, it is more relevant in clinical practice and can be achieved in 95% of patients according to this strategy.

In addition, 84% of those taking intermittent dosing were able to maintain platelet counts at ≥50×109L, which is the platelet count target recommended in the prescribing information.

In general, eltrombopag dose adjustments should be based on the patient's specific condition and physician recommendations. While ensuring the therapeutic effect, reducing the frequency and dosage of drug intake as much as possible can help improve the patient's quality of life and reduce the risk of potential drug side effects.